Clinical trial
International Treatment-extension Study in Adult Participants With Multiple…
NCT05669989 · Sanofi, Industry · Active, not recruiting
Key facts
| NCT number | NCT05669989 |
|---|---|
| Title | International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab |
| Official title | International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study |
| Lead sponsor | Sanofi, Industry |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Plasma Cell Myeloma |
| Intervention type | Drug |
| Interventions | Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib |
| Enrollment | 70 |
| Start date | Apr 5, 2023 |
| Primary completion | Nov 30, 2026 |
| Completion | Nov 30, 2026 |
| First posted | Jan 3, 2023 |
| Last update posted | Jan 23, 2025 |
| Countries | Australia, Brazil, Chile, China, Czechia, Finland, France, Greece, Italy, Japan, New Zealand, Russia and 5 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: